Apollomics unveiled promising findings from the Veneto Institute of Oncology regarding the efficacy of vebreltinib in a patient diagnosed with Glioblastoma Multiforme (GBM) with PTPRZ-MET fusion during the European Society of Medical Oncology Congress (ESMO) 2023, held in Madrid, Spain from October 20-24, 2023. Following the announcement, Apollomics Inc.’s stock witnessed a notable surge.
At the time of this publication, Apollomics Inc stock (APLM) has witnessed a surge.
APLMApollomics Inc
Current Price: $0.93
Change : +0.36
Change (%): (63.75%)
Volume: 66.6M
Source: Tomorrow Events Market Data
The patient, previously treated with radiotherapy and temozolomide, exhibited an impressive Partial Response (PR) after an 8-week course of vebreltinib monotherapy while participating in the SPARTA study (NCT03175224).
Dr. Guo-Liang Yu, Ph.D., co-founder, Chairman, and Chief Executive Officer of Apollomics, expressed satisfaction with the positive clinical outcomes. “PTPRZ-MET fusions are recognized for triggering aggressive forms of GBM and are linked with grim prognoses. We are gratified by the favorable clinical results in patients grappling with this lethal disease, underscoring the potential of vebreltinib as a groundbreaking treatment for individuals afflicted by MET alterations,” stated Dr. Yu. He further added, “We are also encouraged by the strides made in our vebreltinib development initiatives targeting solid tumors characterized by diverse MET alterations.” Despite the encouraging results, it should be noted that this data may not conclusively forecast efficacy in a broader GBM patient population.
The GBM with MET fusion indication remains a focal point for Apollomics and its partner in China, Avistone Biotechnology. Avistone is sponsoring an active-controlled phase 2/3 study evaluating vebreltinib for the treatment of GBM with PTPRZ-MET fusion. The company has engaged in discussions with the National Medical Products Administration (NMPA) concerning a supplemental New Drug Application (NDA) for this indication and has recently garnered priority review status from the NMPA.
Earlier on October 23, Apollomics Inc. unveiled compelling efficacy and safety data derived from the KUNPENG clinical trial for its pioneering drug, vebreltinib, during the ESMO 2023. Despite the initial announcement, the stock experienced a temporary decline.
The demonstrated efficacy of Vebreltinib in treating GBM with PTPRZ-MET fusion marks a significant milestone for Apollomics in advancing innovative therapies for cancer patients.
